These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
    Author: Blais L, Beauchesne MF, Forget A.
    Journal: Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647.
    Abstract:
    BACKGROUND: The combination of inhaled corticosteroids and long-acting inhaled beta(2)-adrenergic-agonists has become the standard therapy for many patients with moderate to severe persistent asthma. Whether the differences between budesonide/formoterol and fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting is unknown. OBJECTIVES: This study compared the use of healthcare services between new users of budesonide/formoterol and fluticasone/salmeterol in a single inhaler between 2002 and 2004. METHODS: A 12-month population-based retrospective cohort study using administrative health care databases was conducted. Asthma patients 16-65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol. The rate of emergency department (ED) visits for asthma, hospitalizations for asthma, claims for oral corticosteroids, and visits to a respiratory specialist were compared between the two groups using Poisson regression models. The mean number of doses of short-acting beta(2)-adrenergic-agonists (SABA) per week was compared between the two groups using a linear regression model. RESULTS: Users of budesonide/formoterol were found to be less likely to have an ED visit for asthma (adjusted RR=0.72; 95% CI: 0.54-0.96), a hospitalization for asthma (adjusted RR=0.50; 95% CI: 0.25-0.99), a claim for oral corticosteroids (adjusted RR=0.83; 95% CI: 0.72-0.95), and use SABA (adjusted mean difference=-1.1 dose per week; 95% CI: -1.7; -0.5) than patients treated with fluticasone/salmeterol. CONCLUSION: Our study has found that subjects initiating ICS/LABA treatment with budesonide/formoterol had better outcomes than those initiating treatment with fluticasone/salmeterol.
    [Abstract] [Full Text] [Related] [New Search]